PE20011268A1 - Composiciones farmaceuticas que comprenden una dispersion de solidos amorfos de [(1s)-bencil-(2r)-hidroxi-3-((3r,4s)-dihidroxi-pirrolidin-1-il)-3-oxipropil]amida del acido 5-cloro-1h-indol-2-carboxilico en un polimero que aumenta la concentracion com - Google Patents

Composiciones farmaceuticas que comprenden una dispersion de solidos amorfos de [(1s)-bencil-(2r)-hidroxi-3-((3r,4s)-dihidroxi-pirrolidin-1-il)-3-oxipropil]amida del acido 5-cloro-1h-indol-2-carboxilico en un polimero que aumenta la concentracion com

Info

Publication number
PE20011268A1
PE20011268A1 PE2001000250A PE2001000250A PE20011268A1 PE 20011268 A1 PE20011268 A1 PE 20011268A1 PE 2001000250 A PE2001000250 A PE 2001000250A PE 2001000250 A PE2001000250 A PE 2001000250A PE 20011268 A1 PE20011268 A1 PE 20011268A1
Authority
PE
Peru
Prior art keywords
polymer
oxypropyl
indol
pyrrolidin
dihydroxy
Prior art date
Application number
PE2001000250A
Other languages
English (en)
Inventor
Walter C Babcock
Marshall D Crew
Dwayne Thomas Friesen
Ravi Mysore Shanker
Douglas Alan Lorenz
Chris Macri
James Alan Schriver Nightingale
Bruno Caspar Hancock
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20011268A1 publication Critical patent/PE20011268A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UNA DISPERSION DE SOLIDO AMORFO DE 10% A 60% EN PESO DE [(1S)-BENCIL-(2R)-HIDROXI-3-((3R,4S)-DIHIDROXI-PIRROLIDIN-1-IL)-3-OXIPROPIL]AMIDA DEL ACIDO 5-CLORO-1H-INDOL-2-CARBOXILICO EN UN POLIMERO QUE AUMENTA LA CONCENTRACION DONDE DICHO POLIMERO ES UN POLIMERO IONIZABLE SELECCIONADO DE POLIMORES CELULOCICOS IONIZABLES, NO ISONIZABLES, TAL COMO HIDROXIPROPIL METILCELULOSA, HIDROXIPROPILCELULOSA, METILCELULOSA ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION DE LA COMPOSICION Y FORMAS DE DOSIFICACION DE LIBERACION INMEDIATA, RETRASADA, CONTROLADA O SOSTENIDAS LAS CUALES COMPRENDEN DICHAS DISPERSIONES SOLIDAS Y EXCIPIENTES. LAS COMPOSICION ACTUAN COMO INHIBIDOR DE LA GLUCOGENO FOSFORILASA Y ES UTIL PARA EL TRATAMIENTO DE DIABETES
PE2001000250A 2000-03-16 2001-03-15 Composiciones farmaceuticas que comprenden una dispersion de solidos amorfos de [(1s)-bencil-(2r)-hidroxi-3-((3r,4s)-dihidroxi-pirrolidin-1-il)-3-oxipropil]amida del acido 5-cloro-1h-indol-2-carboxilico en un polimero que aumenta la concentracion com PE20011268A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19012500P 2000-03-16 2000-03-16

Publications (1)

Publication Number Publication Date
PE20011268A1 true PE20011268A1 (es) 2001-12-12

Family

ID=22700102

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000250A PE20011268A1 (es) 2000-03-16 2001-03-15 Composiciones farmaceuticas que comprenden una dispersion de solidos amorfos de [(1s)-bencil-(2r)-hidroxi-3-((3r,4s)-dihidroxi-pirrolidin-1-il)-3-oxipropil]amida del acido 5-cloro-1h-indol-2-carboxilico en un polimero que aumenta la concentracion com

Country Status (16)

Country Link
US (2) US20010053791A1 (es)
EP (1) EP1263433A2 (es)
JP (2) JP2003526666A (es)
AR (2) AR028253A1 (es)
AU (1) AU2001240978A1 (es)
CA (1) CA2403233A1 (es)
CO (1) CO5271644A1 (es)
GT (1) GT200100039A (es)
MX (1) MXPA02009098A (es)
PA (1) PA8513701A1 (es)
PE (1) PE20011268A1 (es)
SV (1) SV2002000342A (es)
TN (1) TNSN01041A1 (es)
TW (1) TW200304377A (es)
UY (1) UY26615A1 (es)
WO (1) WO2001068092A2 (es)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
JP2004534812A (ja) 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク 薬物および中性ポリマーの分散物の医薬組成物
DE60238193D1 (de) * 2001-06-22 2010-12-16 Pfizer Prod Inc Pharmazeutische zusammensetzungen, enthaltend adsorbate eines arzneimittels in amorpher form
BR0211028A (pt) * 2001-06-22 2004-06-15 Pfizer Prod Inc Solução aquosa, método para formação de associações de fármaco e polìmero, composições farmacêuticas, método para formação de uma composição farmacêutica e produto
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
EP2957281A1 (en) * 2001-09-21 2015-12-23 Egalet Ltd. Polymer release system
GB0126716D0 (en) * 2001-11-07 2002-01-02 Advanced Phytonics Ltd Method for the production of particles
EP1473033A1 (en) * 2002-01-16 2004-11-03 Kowa Company Ltd. Medicinal composition containing 2,2-dichloro-12-(4-chlorophenyl)dodecanoic acid
EP1920766B1 (en) * 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
JP2005523262A (ja) 2002-02-01 2005-08-04 ファイザー・プロダクツ・インク 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物
KR100758045B1 (ko) * 2002-02-01 2007-09-11 화이자 프로덕츠 인크. 압력 노즐을 이용하여 균질한 분무 건조된 비결정질 고체약물 분산제를 제조하는 방법
JP2005517690A (ja) * 2002-02-01 2005-06-16 ファイザー・プロダクツ・インク 固体薬物分散物を含有する即時放出剤形
JP4865989B2 (ja) * 2002-02-01 2012-02-01 ベンド・リサーチ・インコーポレーテッド 改良された噴霧乾燥装置を使用する均質な噴霧乾燥された固体の非晶質薬物分散物を製造する方法
GB0203421D0 (en) * 2002-02-13 2002-04-03 Alizyme Therapeutics Ltd Composition
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
DE10215908B4 (de) * 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10215907A1 (de) * 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10225635C1 (de) * 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
ATE443041T1 (de) * 2002-07-11 2009-10-15 Sanofi Aventis Deutschland Harnstoff- und urethan-substituierte acylharnstoffe, verfahren zu deren herstellung und deren verwendung als arzneimittel
CA2496441C (en) * 2002-08-12 2010-03-16 Pfizer Products Inc. Pharmaceutical compositions of semi-ordered drugs and polymers
DE602004031096D1 (de) 2003-03-26 2011-03-03 Egalet As Morphin-system mit kontrollierter freisetzung
FR2857591B1 (fr) * 2003-07-17 2007-11-02 Ethypharm Sa Particules comprenant un principe actif sous forme de co-precipite
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
BRPI0413277A (pt) * 2003-08-04 2006-10-10 Pfizer Prod Inc composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
JP4505859B2 (ja) * 2003-08-08 2010-07-21 味の素株式会社 ナテグリニド含有製剤
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
BRPI0418330A (pt) * 2003-12-31 2007-05-02 Pfizer Prod Inc composições sólidas de drogas de solubilidade baixa e poloxámeros
US20110027357A1 (en) * 2004-02-18 2011-02-03 Isaac Gilinski Compositions and methods for timed release of water-soluble nutritional supplements
US8158138B1 (en) 2004-05-20 2012-04-17 Fougera Pharmaceuticals, Inc. Urea compositions and their methods of manufacture
US8207232B2 (en) * 2004-05-28 2012-06-26 Bend Research, Inc. Pharmaceutical compositions with enhanced performance
AU2005253957B2 (en) * 2004-06-08 2011-08-25 Janssen Pharmaceutica Nv Pharmaceutical compositions
US20090298745A1 (en) * 2004-12-02 2009-12-03 Gerard Hugh Thomas Treatment of Diabetes with Glycogen Phosphorylase Inhibitors
EP1855652B1 (en) 2005-01-28 2015-12-02 Bend Research, Inc Drying of drug-containing particles
US8617604B2 (en) * 2005-02-03 2013-12-31 Bend Research, Inc. Pharmaceutical compositions with enhanced performance
EP1871363A4 (en) * 2005-03-30 2009-01-21 Genpharm Inc COMBINED STAGE PROCESS FOR PHARMACEUTICAL COMPOSITIONS
CA2611081C (en) * 2005-06-03 2016-05-31 Egalet A/S A drug delivery system for delivering active substances dispersed in a dispersion medium
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
RU2408368C2 (ru) 2005-06-27 2011-01-10 Биовэйл Лэборэториз Интернэшнл С.Р.Л. Препараты соли бупропиона с модифицированным высвобождением
WO2007056205A2 (en) * 2005-11-04 2007-05-18 Eastman Chemical Company Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
DK3219705T3 (da) 2005-12-28 2020-04-14 Vertex Pharma Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
EP2001498A4 (en) * 2006-03-20 2013-01-23 Vertex Pharma PHARMACEUTICAL COMPOSITIONS
RS20090406A (en) 2006-03-20 2010-12-31 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
CA2669324C (en) * 2006-11-13 2012-06-19 Kyorin Pharmaceutical Co., Ltd. Method for preparing sustained release tablet
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
EP1938804A1 (en) * 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist
MX2009006806A (es) * 2006-12-22 2009-08-27 Vertex Pharma Secado por rocio fluidizado.
CA2674536C (en) * 2007-01-16 2016-07-26 Egalet A/S Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
CA2687192C (en) 2007-06-04 2015-11-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
US20090004281A1 (en) * 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
EP4008314A3 (en) * 2007-08-21 2022-11-09 Board of Regents, The University of Texas System Thermo-kinetic mixing for pharmaceutical applications
US8486423B2 (en) 2007-08-21 2013-07-16 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
US8518381B2 (en) * 2008-03-28 2013-08-27 The Procter & Gamble Company Processes of making oral compositions containing gel networks
EP2285351A2 (en) * 2008-04-15 2011-02-23 Schering Corporation Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas
JP2011516613A (ja) * 2008-04-15 2011-05-26 シェーリング コーポレイション 好ましくはポサコナゾールおよびｈｐｍｃａｓを含む固体分散物中の経口用薬学的組成物
DE102008022520A1 (de) * 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
US9005660B2 (en) 2009-02-06 2015-04-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
WO2010149169A2 (en) 2009-06-24 2010-12-29 Egalet A/S Controlled release formulations
JP5757681B2 (ja) 2009-08-12 2015-07-29 富士フイルム株式会社 セルロース誘導体、樹脂組成物、成形体及びその製造方法並びに電気電子機器用筐体
TWI461213B (zh) * 2009-11-05 2014-11-21 Fmc Corp 作為藥物賦形劑之微晶纖維素及磷酸鈣之組合物
EP2389934A1 (en) * 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-Release Tablet Formulations of Pregabalin
MY182136A (en) * 2010-11-24 2021-01-18 Melinta Subsidiary Corp Pharmaceutical compositions
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
US9555001B2 (en) * 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013169523A1 (en) * 2012-05-07 2013-11-14 Bpsi Holdings, Llc. Solubility enhanced compositions
US8313774B1 (en) 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition
CA2877183A1 (en) 2012-07-06 2014-01-09 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
US9713594B2 (en) 2012-09-11 2017-07-25 Bend Research, Inc. Methods for making pharmaceutical solid dosage forms of spray-dried dispersions
WO2014135967A1 (en) 2013-03-06 2014-09-12 Capsugel Belgium Nv Curcumin solid lipid particles and methods for their preparation and use
US20160346198A1 (en) * 2014-02-05 2016-12-01 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
EP3209960A1 (en) * 2014-10-23 2017-08-30 Bend Research, Inc. Spray nozzle and process for making nanoparticles
JP6650933B2 (ja) 2014-10-31 2020-02-19 ベンド リサーチ， インコーポレイテッド マトリックス中に分散された活性薬剤ドメインを形成するためのプロセス
US11324699B2 (en) 2014-12-04 2022-05-10 Capsugel Belgium Nv Lipid multiparticulate formulations
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
CN110475557B (zh) * 2017-01-20 2023-06-20 星座制药公司 固体分散体
WO2021076920A1 (en) 2019-10-16 2021-04-22 Capsugel Belgium Nv Method and composition for increasing muscle protein synthesis
JP2023506222A (ja) 2019-12-10 2023-02-15 カプスゲル・ベルジャン・ナムローゼ・フェンノートシャップ 脂質マトリックスコアおよび活性成分を含有する粒子
EP4262805A1 (en) * 2020-12-16 2023-10-25 Merck Sharp & Dohme LLC Mini-tablet dosage form of a viral terminase inhibitor and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US31547A (en) * 1861-02-26 Improvement in polishing iron bars and rods
US27614A (en) * 1860-03-27 Improvement in cultivators
US3146A (en) * 1843-06-24 Improvement in friction-matches
ES2061623T3 (es) * 1987-03-02 1994-12-16 Brocades Pharma Bv Procedimiento para la obtencion de una composicion farmaceutica y un granulado farmaceutico.
US4999200A (en) * 1987-12-09 1991-03-12 Marion Laboratories Psyllium tablet composition, method of manufacture and method of use
DE68916983T2 (de) * 1988-02-25 1995-01-19 Yamanouchi Europ Bv Verfahren zur Herstellung eines pharmazeutischen Granulats.
JP3155028B2 (ja) * 1991-06-10 2001-04-09 大川原化工機株式会社 噴霧乾燥造粒装置
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
DE4220782A1 (de) * 1992-06-25 1994-01-05 Basf Ag Verfahren zur Herstellung von festen pharmazeutischen Retardformen
GB9421836D0 (en) * 1994-10-28 1994-12-14 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms of hydrophobic substances
GB9511220D0 (en) * 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
DE69628276T2 (de) * 1995-07-26 2004-04-08 Kyowa Hakko Kogyo Co., Ltd. Zubereitung von xanthinderivaten als feste dispersion
US5837292A (en) * 1996-07-03 1998-11-17 Yamanouchi Europe B.V. Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
JP3585654B2 (ja) * 1996-07-11 2004-11-04 株式会社パウダリングジャパン ２段乾燥式スプレードライヤー装置
AU713462B2 (en) * 1996-07-12 1999-12-02 Daiichi Pharmaceutical Co., Ltd. Quickly disintegrable compression-molded materials and process for producing the same
DE19637082A1 (de) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
US5952322A (en) * 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
TW486370B (en) 1996-12-25 2002-05-11 Yamanouchi Pharma Co Ltd Rapidly disintegrable pharmaceutical composition
US5976577A (en) * 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
DK0901786T3 (da) * 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
US5955107A (en) * 1997-12-12 1999-09-21 Fmc Corporation Pharmaceutical suspension tablet compositions
JP2000072676A (ja) 1998-09-01 2000-03-07 Taiho Yakuhin Kogyo Kk 吸収を改善した医薬組成物
ES2307482T3 (es) 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
EP1027887B1 (en) * 1999-02-10 2008-08-13 Pfizer Products Inc. Matrix controlled release device
EP1027888B1 (en) 1999-02-10 2009-06-10 Pfizer Products Inc. Osmotic system for delivery of solid amorphous dispersions of drugs
US6296149B1 (en) 1999-04-16 2001-10-02 Depuy Orthopaedics, Inc. Monomer delivery device for bone cement delivery system
US6223455B1 (en) * 1999-05-03 2001-05-01 Acusphere, Inc. Spray drying apparatus and methods of use
YU35302A (sh) 1999-12-23 2005-03-15 Pfizer Products Inc. Dozirani oblik leka sa inicijalnim hidrogelom
DZ3227A1 (fr) * 1999-12-23 2001-07-05 Pfizer Prod Inc Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form

Also Published As

Publication number Publication date
WO2001068092A2 (en) 2001-09-20
JP2007182449A (ja) 2007-07-19
AU2001240978A1 (en) 2001-09-24
WO2001068092A3 (en) 2002-03-21
AR028253A1 (es) 2003-04-30
TW200304377A (en) 2003-10-01
TNSN01041A1 (fr) 2005-11-10
US20010053791A1 (en) 2001-12-20
PA8513701A1 (es) 2002-10-24
US20030185891A1 (en) 2003-10-02
JP2003526666A (ja) 2003-09-09
EP1263433A2 (en) 2002-12-11
UY26615A1 (es) 2001-10-25
GT200100039A (es) 2001-12-31
MXPA02009098A (es) 2003-03-12
CO5271644A1 (es) 2003-04-30
CA2403233A1 (en) 2001-09-20
AR040281A2 (es) 2005-03-23
US7235260B2 (en) 2007-06-26
SV2002000342A (es) 2002-07-16

Similar Documents

Publication Publication Date Title
PE20011268A1 (es) Composiciones farmaceuticas que comprenden una dispersion de solidos amorfos de [(1s)-bencil-(2r)-hidroxi-3-((3r,4s)-dihidroxi-pirrolidin-1-il)-3-oxipropil]amida del acido 5-cloro-1h-indol-2-carboxilico en un polimero que aumenta la concentracion com
AR075028A1 (es) Composicion farmaceutica solida que comprende amlodipina y losartan
PE20041065A1 (es) Composiciones farmaceuticas que comprenden ester de testosterona y aceite de ricino
EA200800161A1 (ru) Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций
BR112012006686B8 (pt) compostos de amida substituída, composições farmacêuticas contendo os ditos compostos, e uso dos mesmos para prevenir e/ou tratar doenças causadas pelo lpa
ATE424848T1 (de) Pharmazeutische zusammensetzungen für die kontrollierte freigabe von biologischen wirkstoffen
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
EA201100814A1 (ru) Фармацевтические формы применения, содержащие нифедипин или низолдипин и антагонист ангиотензина-ii и/или диуретик
EA200001125A1 (ru) Гелеобразные фармацевтические композиции
PE20020802A1 (es) COMPUESTO DE LACTAMA COMO INHIBIDOR DE LA LIBERACION DEL PEPTIDO ß-AMILOIDE
PE20100265A1 (es) Nuevas composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion
TW200609001A (en) Particulate-stabilized injectable pharmaceutical compositions of posaconasole
CL2009000860A1 (es) Compuestos derivados de 4-fenil-4-metil-5,6-dihidro-4h-1,3-tiazina-2-amina; composiciones farmaceuticas que los contienen; y uso de los compuestos en la preparacion de medicamentos inhibidores de bace, utiles para el tratamiento de trastornos mediados por esta enzima, tal como la enfermedad de alzheimer.
MX2010005292A (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
UY31406A1 (es) "producto de dispersion solida que contiene un compuesto a base de n-aril urea".
PA8533901A1 (es) Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis
PE20220751A1 (es) Composiciones solidas que comprenden un agonista del glp-1, un inhibidor del sglt2 y una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico
PE20060464A1 (es) Composicion farmaceutica que comprende flibanserina para el tratamiento de trastornos sexuales
PE20130009A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
CL2011000144A1 (es) Compuestos derivados de benzo (1,4) dioxin-2-ilmetil-sulfamida; composiciones farmaceuticas que los contienen; proceso para prepararlos y uso en el tratamiento de la ansiedad, epilepsia, dolor, abuso de sustancias, trastornos relacionados, entre otros.
EA200700130A1 (ru) Композиции, содержащие стронций и витамин d, и их применение
MX2009012742A (es) Ingrediente activo novedoso en cicatrizacion y uso del mismo.
BRPI0511466B8 (pt) agonistas peptídicos do receptor de vasopressina, composição farmacêutica compreendendo os referidos agonistas e uso destes
ATE548034T1 (de) Pharmazeutische zusammensetzungen mit droxidopa
EA201200185A1 (ru) Фармацевтическая композиция для пероральной доставки дииндолилметана

Legal Events

Date Code Title Description
FD Application declared void or lapsed